HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?
Key Points
The executive sold 9,219 shares at $41.23 per share on August 17, 2026, generating ~$380,100.
The transaction reduced the insider's direct equity position by 10%, while total beneficial ownership decreased by 4%.
This activity involved 9,219 options exercised at $19 per share and immediately sold.
- 10 stocks we like better than HeartFlow ›
Campbell Rogers, Chief Medical Officer at HeartFlow, Inc. (NASDAQ:HTFL), executed a sale of 9,219 shares on August 17, 2026, totaling approximately $380,100 according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold | 9,219 |
| Transaction value | $380,100 |
| Post-transaction shares (total) | 231,999 |
| Post-transaction shares (directly held) | 86,459 |
| Post-transaction shares (indirectly held) | 145,540 |
| Post-transaction value | $9.73 million |
Transaction value based on SEC Form 4 weighted average sale price ($41.23); post-transaction value based on August 17, 2026 market close ($41.94).
Key questions
- What initiated this disposal of equity?
The transaction was part of a Rule 10b5-1 trading plan adopted on December 12, 2025, which allows insiders to execute pre-planned trades to manage personal liquidity. - How does this affect the Chief Medical Officer's total position?
Campbell remains a significant shareholder with a 0.27% stake, maintaining 86,459 shares directly and 145,540 shares indirectly through the Campbell Rogers 2019 Irrevocable Trust, the CR Asset Protection Trust of 2023, a Spouse's Trust, and The Campbell Rogers Revocable Trust. - What is the status of the insider's remaining equity incentives?
Following this exercise, Campbell continues to hold 82,972 options that vest monthly through August 2029, maintaining long-term alignment with the company's performance. - How has the stock performed leading up to this transaction?
HeartFlow was priced at $45.23 as of the August 18, 2026 market close, having achieved a one-year return of 35% as of the transaction date.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-18) | $45.23 |
| Market Capitalization | $3.9 billion |
| Revenue (TTM) | $212.1 million |
| Net Income (TTM) | -$118.4 million |
Company Snapshot
- HeartFlow develops and commercializes the HeartFlow Platform, an artificial intelligence-powered diagnostic solution that creates three-dimensional digital replicas of patient hearts from coronary computed tomography angiography scans to enable non-surgical assessment of coronary artery disease.
- The company generates revenue through licensing its proprietary HeartFlow Platform to healthcare providers and institutions, leveraging advanced computational fluid dynamics technology to deliver personalized cardiac diagnostics that reduce unnecessary invasive procedures.
- HeartFlow primarily serves hospitals, cardiology centers, and healthcare systems globally that seek to improve diagnostic accuracy and patient outcomes in the management of coronary artery disease.
HeartFlow is a global medical technology company with a market cap of $3.9 billion, operating at scale with 843 employees and generating $212.1 million in trailing 12-month revenue. The company's competitive advantage derives from its proprietary artificial intelligence and computational fluid dynamics algorithms that provide clinically validated, non-invasive coronary artery disease assessment, positioning it as a differentiated player in the cardiac diagnostics market.
What this transaction means for investors
HeartFlow Chief Medical Officer Campbell Rogers' Aug. 17 sale of company stock came at a time when shares were rising. His disposition at a sale price of $41.23 occurred just days before the stock reached a 52-week high of $47.64 on Aug. 20.
Even so, Rogers' transaction was non-discretionary in nature, since it was executed as part of a pre-arranged Rule 10b5-1 trading plan. The 9,219 shares sold came from stock options, which temporarily increased his direct holdings by about 10% before they were disposed of, leaving him with 86,459 direct shares.
Post-disposal, Rogers retains a significant equity stake in HeartFlow. Along with his direct holdings, he has indirect shares in various trusts in addition to nearly 83,000 stock options. Given these factors, his Aug. 17 disposition does not appear to be a cause for investor concern.
HeartFlow stock is up because of strong business performance. The company posted second quarter sales of $64.1 million. This represents an outstanding 48% year-over-year increase, illustrating the demand for its technology.
Should you buy stock in HeartFlow right now?
Before you buy stock in HeartFlow, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and HeartFlow wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,621!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,335,314!*
Now, it’s worth noting Stock Advisor’s total average return is 976% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 20, 2026.
Robert Izquierdo has positions in HeartFlow. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
